3157DrugBank APRD00474Chemical dataFormula C23H25N5O5Mol. mass 451.475 g/molPharmacokinetic dataBioavailability 65%Protein binding 98%Metabolism HepaticHalf life doxazosin 2 mg hoursExcretion ?Therapeutic considerationsPregnancy cat. ?Legal status ? Prescription onlyRoutes oralDoxazosin mesylate, a quinazoline compound.

22, 2005, the US FDA approved a sustained release form of doxazosin 2 mg to be marketed as Cardura® XL.It is an alpha blocker doxazosin 2 mg to treat high blood pressure doxazosin 2 mg benign prostatic hyperplasia.On February doxazosin 2 mg 2005, the US FDA approved a sustained doxazosin 2 mg form of doxazosin, to be marketed as Cardura® XL.It is an alpha blocker used to treat high doxazosin 2 mg pressure and benign prostatic hyperplasia.On February 22, 2005, the US FDA approved a sustained release form of doxazosin, to be marketed as Cardura® XL.It is an alpha blocker used to treat high blood pressure and doxazosin 2 mg prostatic hyperplasia.On February 22, 2005, the US FDA approved a sustained release form of doxazosin, to be marketed as Cardura® XL.It is an alpha-1 adrenergic receptor blocker which inhibits the binding of norepinephrine doxazosin 2 mg alpha receptors in the autonomic nervous system. The primary effect of this doxazosin 2 mg is relaxed vascular smooth muscle tone (vasodilation), which decreases peripheral vascular resistance, leading to decreased blood.

blocker which inhibits the binding of norepinephrine to alpha receptors in the autonomic nervous system. doxazosin 2 mg primary effect of this blockage.